LEADER 02164nas 2200589-a 450 001 9910131240203321 005 20240413023035.0 011 $a1344-722X 035 $a(DE-599)ZDB1466042-8 035 $a(CKB)110978978956680 035 $a(CONSER)sn-89013033- 035 $a(EXLCZ)99110978978956680 100 $a19890124a19889999 --- - 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCDNLAO newsletter $eforum for the Conference of Directors of National Libraries in Asia and Oceania 210 $aTokyo, Japan $cNational Diet Library$d1988- 215 $a1 online resource 300 $aTitle from caption. 311 08$aPrint version: CDNLAO newsletter : 0914-6601 (DLC)sn 89013033 (OCoLC)19054586 606 $aNational libraries$zAsia$vPeriodicals 606 $aLibrary cooperation$zAsia$vPeriodicals 606 $aNational libraries$zOceania$vPeriodicals 606 $aLibrary cooperation$zOceania$vPeriodicals 606 $aLibrary cooperation$2fast$3(OCoLC)fst00997693 606 $aNational libraries$2fast$3(OCoLC)fst01033614 606 $aBibliothèques nationales$zAsie$vPériodiques 606 $aCoopération entre bibliothèques$zAsie$vPériodiques 606 $aBibliothèques nationales$zOcéanie$vPériodiques 606 $aCoopération entre bibliothèques$zOcéanie$vPériodiques 607 $aAsia$2fast 607 $aOceania$2fast 608 $aPeriodicals.$2fast 615 0$aNational libraries 615 0$aLibrary cooperation 615 0$aNational libraries 615 0$aLibrary cooperation 615 7$aLibrary cooperation. 615 7$aNational libraries. 615 6$aBibliothèques nationales 615 6$aCoopération entre bibliothèques 615 6$aBibliothèques nationales 615 6$aCoopération entre bibliothèques 712 02$aKokuritsu Kokkai Toshokan (Japan) 712 12$aConference of Directors of National Libraries in Asia and Oceania. 906 $aJOURNAL 912 $a9910131240203321 920 $aexl_impl conversion 996 $aCDNLAO newsletter$92147510 997 $aUNINA LEADER 04112nam 2200913z- 450 001 9910619470303321 005 20221025 010 $a3-0365-5390-8 035 $a(CKB)5670000000391571 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93224 035 $a(oapen)doab93224 035 $a(EXLCZ)995670000000391571 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUpdates in Management of SARS-CoV-2 Infection 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (198 p.) 311 08$a3-0365-5389-4 330 $aSevere acute respiratory syndrome coronavirus 2 (SARS?CoV?2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID?19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus?related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time?consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS?CoV?2 infection. 606 $aMedicine$2bicssc 610 $aangiotensin 1 receptor (AT1R) 610 $aangiotensin II 610 $aantigen detection 610 $aartificial intelligence 610 $aAT1R concentration 610 $aCharlson Comorbidities Index 610 $achildren 610 $aclinical outcome 610 $aclinical presentation 610 $acluster analysis 610 $aco-infections 610 $acoronavirus disease 2019 610 $acoronavirus disease 2019 (COVID-19) 610 $aCOVID-19 610 $aCOVID-19 diagnosis 610 $aCOVID-19 pneumonia 610 $acritical care 610 $acytokines 610 $aCytomegalovirus 610 $adiagnosis 610 $aepidemiology 610 $aindividualized management 610 $ainflammation 610 $ainterleukin-6 610 $akidney failure 610 $aliver functional tests 610 $aliver markers 610 $alongitudinal cluster 610 $amedical imaging 610 $ameta-analysis 610 $amethodological credibility 610 $amorbidity 610 $amortality 610 $an/a 610 $apandemic 610 $aPCR test 610 $apersonalized medicine 610 $aprognosis 610 $arapid diagnostic test 610 $aSARS-CoV-2 610 $asevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 610 $aseverity 610 $asymptomatology 610 $asymptoms' severity 610 $asystematic umbrella review 610 $atherapy 610 $atocilizumab 610 $atrial sequential analysis 615 7$aMedicine 700 $aFlisiak$b Robert$4edt$01328782 702 $aFlisiak$b Robert$4oth 906 $aBOOK 912 $a9910619470303321 996 $aUpdates in Management of SARS-CoV-2 Infection$93038948 997 $aUNINA